MAPT - Denali Therapeutics sees cash runway into 2028
2025-01-13 12:32:12 ET
More on Denali Therapeutics
- Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
- Denali Has A Neurodegenerative Edge Despite Market Skepticism
- Denali Therapeutics gets FDA breakthrough therapy designation for its treatment of hunter syndrome
- Denali ALS candidate fails in key study
- Seeking Alpha’s Quant Rating on Denali Therapeutic